PI3K/Akt/CREB activator 1

Name: PI3K/Akt/CREB activator 1
Brand: MedChemExpress
SKU: HY-151527
Rating: 5.0 (2 reviews)

Cat. No.: HY-151527 Purity: 99.10%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).

For research use only. We do not sell to patients.

PI3K/Akt/CREB activator 1 Chemical Structure

CAS No. : 2708177-73-3

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 132	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 132	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 200	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 390	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 600	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 900	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

2 Publications Citing Use of MCE PI3K/Akt/CREB activator 1

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells^[1].
PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Neuro-2a cells
Concentration:	10 and 20 μM
Incubation Time:	48 hours
Result:	Increased the expressions of BDNF and the phosphorylated form of AKT (pAKT) and CREB (pCREB).

In Vivo

PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO)^[1].
PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model^[1]
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 6 weeks
Result:	Promoted the recovery of CBF after BCCAO.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model^[1]
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 5 days
Result:	Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group. Improved cognitive deficits in CCH rat model.

Molecular Weight

381.32

Formula

C₁₉H₁₅F₄NO₃

CAS No.

2708177-73-3

Appearance

Solid

Color

White to off-white

SMILES

O=C(N[C@H](C(O)=O)CC1=CC=C(C=C1)F)/C=C/C2=CC=C(C=C2)C(F)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (655.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6225 mL	13.1123 mL	26.2247 mL
5 mM	0.5245 mL	2.6225 mL	5.2449 mL
10 mM	0.2622 mL	1.3112 mL	2.6225 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.10%

Select Batch:

Data Sheet (276 KB) SDS (251 KB)

COA (246 KB) HNMR (293 KB) LCMS (264 KB)

Handling Instructions (2659 KB)

References

[1]. Feng JH, et, al. Protective Effects of 4-Trifluoromethyl-(E)-cinnamoyl]-L-4-F-phenylalanine Acid against Chronic Cerebral Hypoperfusion Injury through Promoting Brain-Derived Neurotrophic Factor-Mediated Neurogenesis. ACS Chem Neurosci. 2022 Oct 16. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6225 mL	13.1123 mL	26.2247 mL	65.5617 mL
	5 mM	0.5245 mL	2.6225 mL	5.2449 mL	13.1123 mL
	10 mM	0.2622 mL	1.3112 mL	2.6225 mL	6.5562 mL
	15 mM	0.1748 mL	0.8742 mL	1.7483 mL	4.3708 mL
	20 mM	0.1311 mL	0.6556 mL	1.3112 mL	3.2781 mL
	25 mM	0.1049 mL	0.5245 mL	1.0490 mL	2.6225 mL
	30 mM	0.0874 mL	0.4371 mL	0.8742 mL	2.1854 mL
	40 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6390 mL
	50 mM	0.0524 mL	0.2622 mL	0.5245 mL	1.3112 mL
	60 mM	0.0437 mL	0.2185 mL	0.4371 mL	1.0927 mL
	80 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6556 mL